{"chain_id": "chain_000000", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5948914", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5948914, is the following pharmacogenomic claim supported or contradicted: Genotypes GT + TT are not associated with overall survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The paper does not provide data on genotypes labeled as \"GT + TT\" or \"GG\", but it specifies that no association with overall survival was found for certain genotypes of the SNPs studied, including POLR2A N764K, where overall survival was not significantly different between genotypes. This aligns with the claim that there is no association between certain genotypes and overall survival."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2231142 and gemcitabine in Disease:Non-Small Cell Lung Carcinoma (PMCID PMC5948914), what p-value was reported for this association?", "answer": "= 0.080", "response": "The p-value reported for the association between rs2231142 (ABCG2 Q141K) and progression-free survival (PFS) in Non-Small Cell Lung Carcinoma treated with gemcitabine is 0.007 (adjusted). For overall survival (OS), the univariate p-value was 0.017, and the adjusted p-value was 0.080."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "True."}]}
{"chain_id": "chain_000001", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC11732454", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11732454, is the following pharmacogenomic claim supported or contradicted: HLA-A *31:03 is associated with decreased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of HLA-A*31:03 and carbamazepine, lamotrigine, phenytoin in Toxicity (PMCID PMC11732454), what confidence interval was reported?", "answer": "0.13\u20130.27", "response": "A confidence interval for HLA-A*31:03 and its association with drug-induced reactions was not specifically reported in the context of carbamazepine, lamotrigine, or phenytoin in this paper. However, in the context of Stevens-Johnson Syndrome (SJS), the paper reports an odds ratio (OR) of 0.19 with a 95% confidence interval of 0.13\u20130.27 for HLA-A*31:03 among the study subjects."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000002", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4640545", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4640545, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2298771 and carbamazepine in Disease:Epilepsy (PMCID PMC4640545), what p-value was reported for this association?", "answer": "> 0.05", "response": "A p-value of 0.96 was reported for the association between rs2298771 and carbamazepine in epilepsy."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False"}]}
{"chain_id": "chain_000003", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4177494", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4177494, is the following pharmacogenomic claim supported or contradicted: Genotypes GG + GT is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs8099917 and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin in Disease:Hepatitis C virus infection (PMCID PMC4177494), what OR was reported?", "answer": "7.9", "response": "The reported odds ratio (OR) for the association of the rs8099917 G allele with a null response to peginterferon alfa-2a or alfa-2b and ribavirin therapy in hepatitis C virus infection was 7.9."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000004", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC7351433", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC7351433, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study discussed in PMCID PMC7351433 does not focus specifically on a comparison between allele G and allele T in terms of methotrexate concentration. However, the study mentions that certain genotypes associated with alleles are significant, rather than focusing on the alleles themselves. Specifically, the MTHFR rs1801133 TT genotype was associated with higher methotrexate plasma levels, but there is no direct comparison made between the G and T alleles themselves regarding methotrexate concentrations. Therefore, the claim that allele G is not associated with methotrexate concentrations compared to allele T is supported by the absence of such evidence in the paper."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents clinical association. The study investigates the relationship between genetic polymorphisms and clinical outcomes such as plasma methotrexate levels, toxicity, and event-free survival in pediatric patients with acute lymphoblastic leukemia, which are characteristic of clinical association evidence."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1801131 and methotrexate in Other:Acute lymphoblastic leukemia (PMCID PMC7351433), what p-value was reported for this association?", "answer": "> 0.05", "response": "The study reported a p-value of less than 0.05 (*P<0.05*) for the association between the MTHFR rs1801131 AC genotype and decreased hepatic toxicity in pediatric acute lymphoblastic leukemia."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "True."}]}
{"chain_id": "chain_000005", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3909071", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3909071, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs13242038 and heroin in Other (PMCID PMC3909071)?", "answer": 619, "response": "619 controls were included in the study of rs13242038 and heroin dependence."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000006", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5519037", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5519037, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The paper reports that the *CYP3A4* rs35599367 variant (*CYP3A4*22 allele) carriers (which would correspond to CT + TT genotypes) had higher everolimus blood concentrations compared to those with the CC genotype (wild type patients), with a statistically significant association (P = 0.019)."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs776746 and everolimus in Disease:Breast Neoplasms (PMCID PMC5519037), what p-value was reported for this association?", "answer": "> 0.05", "response": "The study reported no statistically significant differences for the association of rs776746 (*CYP3A5*1 allele) with everolimus concentrations, and therefore, no specific p-value for this association was mentioned."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000007", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5207665", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5207665, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with response to bevacizumab in women with Breast Neoplasms as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper PMCID PMC5207665 does not provide information regarding a specific \"Allele A\" versus \"allele G\" association with response to bevacizumab. The study investigates associations between various SNPs within certain genes (TEK, ANGPT1, ANGPT2, MMP9, FGF2, VEGFA) and pathologic complete response (pCR) to bevacizumab, but it does not specifically mention or compare \"Allele A\" to \"allele G\" in the context of response to bevacizumab. Therefore, the claim cannot be assessed as supported or contradicted based on the provided details in the study."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs17577 and bevacizumab in Disease:Breast Neoplasms (PMCID PMC5207665)?", "answer": 33, "response": "The paper PMCID PMC5207665 does not mention a study specifically associating rs17577 with bevacizumab in the context of Breast Neoplasms. Consequently, it does not provide any control numbers specifically for a study on rs17577."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "Since the paper does not mention a study specifically involving rs17577, there is no information on the number of controls for such a study. Therefore, the dataset minimum requirement of N \u2265 30 for study controls cannot be assessed, making the statement false in this context."}]}
{"chain_id": "chain_000008", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC1689719", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC1689719, is the following pharmacogenomic claim supported or contradicted: G6PD deficiency is not associated with Hemolysis when treated with trimethoprim. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper does not specifically mention trimethoprim. However, it addresses the hemolytic effect of several drugs in individuals with G6PD deficiency. Since the paper does not include information about trimethoprim, we cannot determine if G6PD deficiency is associated with hemolysis when treated with this specific drug based on this paper alone. Therefore, the claim is not supported or contradicted by the information provided in PMCID PMC1689719."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents clinical association evidence."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of G6PD deficiency and trimethoprim in Toxicity (PMCID PMC1689719)?", "answer": 8, "response": "The study in PMCID PMC1689719 did not specifically include or mention cases of G6PD deficiency related to trimethoprim. Thus, it provides no information about cases related to trimethoprim toxicity."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": false, "response": "False. The study does not report cases related to trimethoprim; therefore, it does not meet the dataset minimum requirement for study cases."}]}
{"chain_id": "chain_000009", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2850440", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2850440, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with increased risk of Crohn Disease. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The paper reports that allele G (specifically for SNPs rs17234657 and rs17221417) is associated with an increased risk of Crohn Disease, with significant p-values and odds ratios greater than 1, indicating a genetic association."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2542151 (PMCID PMC2850440), what OR was reported?", "answer": "1.0834", "response": "The reported odds ratio (OR) for rs2542151 in the study was 1.0834 for non-Hispanic European ancestry with definite Crohn disease cases, and 1.0446 for non-Hispanic European + unknown ancestry with definite Crohn disease cases."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "False. The confidence intervals for the OR of rs2542151 include the null value of 1.0, indicating no significant association."}]}
{"chain_id": "chain_000010", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5331771", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5331771, is the following pharmacogenomic claim supported or contradicted: Genotypes AG + GG are associated with increased platelet reactivity when treated with aspirin and clopidogrel as compared to genotype AA. Answer one of: supported, contradicted.", "answer": "supported", "response": "The given paper does not specifically investigate or provide results related to genotypes AG, GG, or AA. It instead focuses on polymorphisms in the CYP2C19, P2Y12, and other genes. Therefore, the specific claim regarding genotypes AG, GG, and AA is not addressed in this study. As a result, the paper neither supports nor contradicts this claim. However, based on the options provided, I would be unable to choose either as the paper does not relate to the claim as stated."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2046934 and aspirin, clopidogrel in Efficacy (PMCID PMC5331771), what confidence interval was reported?", "answer": "1.64\u20133.53", "response": "The paper does not specifically report a confidence interval for the study of rs2046934 in relation to the efficacy of treatment with aspirin and clopidogrel. The results related to rs2046934, a polymorphism in the P2Y12 gene, are discussed in terms of associations with high on-treatment platelet reactivity and clinical endpoints, but specific confidence intervals are not provided in the context of efficacy in the study."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "The paper does not specifically provide a confidence interval for an odds ratio (OR) concerning the rs2046934 polymorphism in relation to aspirin and clopidogrel efficiency. Thus, it is not possible to determine from the provided text whether the confidence interval for any OR excludes the null value of 1.0 for this specific polymorphism. Therefore, I would be unable to specify true or false based on the given information."}]}
{"chain_id": "chain_000011", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC6021962", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC6021962, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper's findings would suggest that the claim is supported. The study specifically mentioned that outside the *CYP3A4* and *CYP3A5* loci, no common variants, including allelic variations, were found to be significantly associated with tacrolimus trough concentrations. Therefore, allele T as compared to allele C, without specifying loci that fall under *CYP3A4* and *CYP3A5*, would likely fall into the category of non-significant findings according to the conclusions of the study. This indicates support for the claim that allele T is not associated with tacrolimus trough concentration in the mentioned context."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs10264272 and tacrolimus in Disease:Kidney Transplantation, Disease:Transplantation (PMCID PMC6021962), what p-value was reported for this association?", "answer": "= 0.269", "response": "For the study of rs10264272 and tacrolimus in the context of Kidney Transplantation and Transplantation, the reported p-value was 0.269."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000012", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4039076", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4039076, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased minimal residual disease when treated with asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted. The paper does not discuss an association between specific alleles of GATA3, such as allele A or C, with increased minimal residual disease in treatment regimens involving the mentioned drugs for precursor cell lymphoblastic leukemia-lymphoma. The focus is on inherited GATA3 variant rs3824662 and its association with Ph-like ALL and relapse risk, rather than specific alleles associated with treatment response."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3824662 and asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine, vincristine in Disease:Acute lymphoblastic leukemia (PMCID PMC4039076), what p-value was reported for this association?", "answer": "= 0.039", "response": "The study does not specifically report a p-value for the association of rs3824662 with treatment involving asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine, and vincristine. It focuses on the susceptibility locus for Ph-like ALL (GATA3, rs3824662) with reported p-values for other comparisons: P=2.17\u00d710\u221214 for Ph-like ALL vs. non-ALL controls and P=1.05\u00d710\u22128 for Ph-like ALL vs. non-Ph-like ALL."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True. The reported p-values (P=2.17\u00d710\u221214 and P=1.05\u00d710\u22128) are far below the alpha level of 0.05, indicating statistical significance."}]}
{"chain_id": "chain_000013", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC8602039", "num_turns": 2, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC8602039, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC8602039, rs74569896 is associated with Efficacy, Toxicity, Metabolism/PK outcomes for aspirin, clopidogrel. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC8602039 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMCID PMC8602039 reports quantitative statistics for the association of rs74569896 with MACE outcomes. The paper presents a Hazard Ratio (HR) of 1.90 and a p-value of 1.31 \u00d7 10^-6 in the replication stage for the association of rs74569896 with major adverse cardiovascular events (MACE) outcomes."}]}
{"chain_id": "chain_000014", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5538123", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5538123, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs6313 and risperidone in Other:Schizophrenia (PMCID PMC5538123), what p-value was reported for this association?", "answer": "= 1", "response": "The p-value reported for the association of rs6313 and risperidone in schizophrenia was 0.447."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000015", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3773276", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3773276, is the following pharmacogenomic claim supported or contradicted: CYP2C19 *17 is not associated with post-treatment ADP-stimulated platelet aggregation when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2C19*17 and clopidogrel in Efficacy (PMCID PMC3773276), what p-value was reported for this association?", "answer": "= 0.01", "response": "The p-value reported for the association of CYP2C19*17 with post-treatment ADP-stimulated platelet aggregation, after adjusting for the effects of CYP2C19*2, was 0.69."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "False."}]}
{"chain_id": "chain_000016", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4864175", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4864175, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with risk of cognitive dysfunction due to opioids in people with Neoplasms as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs2160652 and opioids in Disease:Neoplasms (PMCID PMC4864175)?", "answer": 98, "response": "A total of 1586 patients were initially analyzed in the study, but for the specific analysis regarding rs2160652, the number of patients included would be the same as the ones included in the analyses of SNPs, which is 1369 patients as indicated after filtering for Hardy-Weinberg equilibrium and minor allele frequency criteria. However, the exact number for rs2160652 was not directly specified in the data, so the assumption is based on the overall filtered dataset used for SNP analysis."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True"}]}
{"chain_id": "chain_000017", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4519434", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4519434, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3778151 and heroin in Toxicity (PMCID PMC4519434), what p-value was reported for this association?", "answer": "= 3E-3", "response": "The reported p-value for the association of rs3778151 with heroin addiction in the study was 2.4\u00d710^-7."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000018", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5908896", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5908896, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with severity of Neutropenia when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The paper shows that the *STAT-3* rs1053004 polymorphism is associated with GI toxicity but does not report any significant results of the *STAT-3* rs1053004 polymorphism (allele C) concerning the severity of neutropenia. This suggests that allele C is not significantly associated with the severity of neutropenia in this context."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2972164 and fluorouracil, irinotecan, leucovorin in Disease:Colorectal Neoplasms (PMCID PMC5908896), what OR was reported?", "answer": "1.34", "response": "The reported odds ratio (OR) for the rs2972164 polymorphism in the context of fluorouracil, irinotecan, and leucovorin treatment for colorectal neoplasms was 0.36 in the discovery cohort under a dominant model."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "True."}]}
{"chain_id": "chain_000019", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2761685", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2761685, is the following pharmacogenomic claim supported or contradicted: Genotype GG is associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1051375 and verapamil in Disease:Coronary Artery Disease (PMCID PMC2761685), what confidence interval was reported?", "answer": "1.67\u201312.67", "response": "The confidence interval reported for the association between the rs1051375 G/G genotype and the increased risk of the primary outcome with verapamil treatment, compared to those randomized to atenolol, was OR 4.59, 95% CI 1.67-12.67."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000020", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2966859", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2966859, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs9394992 and gemcitabine in Disease:Pancreatic Neoplasms (PMCID PMC2966859), what HR was reported?", "answer": "1.08", "response": "The hazard ratio (HR) reported for rs9394992 in relation to progression-free survival in gemcitabine treatment for pancreatic neoplasms was 1.08."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the HR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000021", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3619396", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3619396, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with risk of Hypersensitivity when treated with sulfamethoxazole / trimethoprim in people with Infection. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs77005399 and sulfamethoxazole / trimethoprim in Disease:Infectious disease (PMCID PMC3619396)?", "answer": 99, "response": "99 cases."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000022", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3798385", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3798385, is the following pharmacogenomic claim supported or contradicted: Genotype CG is associated with increased risk of Neurotoxicity Syndromes when treated with carboplatin, docetaxel and paclitaxel in women with Ovarian Neoplasms as compared to genotypes CC + GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The paper identifies that the SNP rs139887 in the SOX10 gene, where the genotype is CG, is significantly associated with increased risk of moderate to severe neurotoxicity compared to the combination of genotypes CC and GG."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs139887 and carboplatin, docetaxel, paclitaxel in Disease:Ovarian Neoplasms (PMCID PMC3798385), what OR was reported?", "answer": "1.77", "response": "The odds ratio (OR) reported for the SNP rs139887 in the SOX10 gene was 1.77."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The 95% confidence interval for the OR is (1.21, 2.59), which excludes the null value of 1.0."}]}
{"chain_id": "chain_000023", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC9031832", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC9031832, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity and Fetal Alcohol Syndrome as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs1800497 and methylphenidate in Other:Attention Deficit Disorder with Hyperactivity, Other:Fetal Alcohol Syndrome (PMCID PMC9031832)?", "answer": 114, "response": "The study included 114 children diagnosed with ADHD for the examination of rs1800497 and methylphenidate treatment, with the context of Fetal Alcohol Syndrome considered in the analysis."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000024", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC9957000", "num_turns": 2, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC9957000, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC9957000, rs4149056 is associated with PD, Metabolism/PK outcomes for atorvastatin, simvastatin. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "contradicted"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC9957000 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMCID PMC9957000 reports quantitative statistics for this claim. The paper provides odds ratios (ORs) and confidence intervals (CIs) for associations between the SLCO1B1 c.521T>C genotype and changes in statin therapy, but none show a significant association. For example, for simvastatin dose change in TC/CC versus TT genotype, the adjusted OR is 0.42 (95% CI 0.15\u20131.16), and for atorvastatin, the adjusted OR is 1.97 (95% CI 0.43\u20139.04). Neither is statistically significant, indicating a lack of association."}]}
{"chain_id": "chain_000025", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4519434", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4519434, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Based on PMCID PMC4519434, the pharmacogenomic claim is contradicted. The study focuses on the OPRM1 gene, specifically the SNPs rs3778150 and rs1799971. Rs1799971-A was only associated with increased heroin addiction risk in conjunction with the rs3778150-C allele. The paper does not support the claim that the A allele by itself is associated with an increased risk for heroin dependence compared to allele G without the context of the rs3778150-C allele."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents evidence of a clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3823010 and heroin in Toxicity (PMCID PMC4519434), what confidence interval was reported?", "answer": "1.1\u20131.37", "response": "For the study of rs3823010 and heroin in Toxicity (PMCID PMC4519434), the reported confidence interval for the association in European Americans was 1.28 (1.11-1.49)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000026", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4752391", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4752391, is the following pharmacogenomic claim supported or contradicted: Genotype TTA/del is associated with increased response to atenolol, hydrochlorothiazide or metoprolol in people with Hypertension as compared to genotype TTA/TTA. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs201279313 and atenolol, hydrochlorothiazide, metoprolol in Disease:Hypertension (PMCID PMC4752391), what p-value was reported for this association?", "answer": "= 1.10E-07", "response": "The p-value reported for the association of rs201279313 with the blood pressure response to atenolol, hydrochlorothiazide, or metoprolol is 2.5*10^-8."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True"}]}
{"chain_id": "chain_000027", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC12032684", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC12032684, is the following pharmacogenomic claim supported or contradicted: Genotypes CC + CT is associated with increased likelihood of statin-related myopathy when treated with atorvastatin in people with Cardiovascular Disease, Diabetes Mellitus, Acute coronary syndrome or Dyslipidaemia as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs4149056 and atorvastatin in Other:Cardiovascular Disease, Other:Diabetes Mellitus, Other:Acute coronary syndrome, Other:Dyslipidaemia (PMCID PMC12032684), what OR was reported?", "answer": "2.202", "response": "For the study of rs4149056 and atorvastatin in the context of Other:Cardiovascular Disease, Other:Diabetes Mellitus, Other:Acute coronary syndrome, and Other:Dyslipidaemia, the odds ratio (OR) reported was 2.202."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000028", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC11050844", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11050844, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased likelihood of primary graft failure or Kidney Tubular Necrosis, Acute when treated with mycophenolic acid and tacrolimus in people with Kidney Transplantation as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs717620 and mycophenolic acid, tacrolimus in Other:Kidney Transplantation (PMCID PMC11050844), what p-value was reported for this association?", "answer": "= 0.038", "response": "The reported p-value for the association of the ABCC2 -24C>T C allele with acute graft rejection and/or ATN in kidney transplant recipients treated with mycophenolic acid and tacrolimus is p = 0.038."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000029", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC8673616", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC8673616, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. \n\nThe paper indicates that the G allele of the OPRM1 rs1799971 SNP is not associated with the methadone dose in people with Opioid-Related Disorders, as shown by the results where there is no statistically significant association between allele G and methadone dose."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs10485058 and methadone in Other:Opioid-Related Disorders (PMCID PMC8673616)?", "answer": 1165, "response": "The study included 1,165 cases for the analysis of rs10485058 and methadone dose in participants with Opioid-Related Disorders."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000030", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC8291172", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC8291172, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with decreased likelihood of Hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3786362 and capecitabine in Other:Colorectal Neoplasms (PMCID PMC8291172), what OR was reported?", "answer": "0.38", "response": "The reported odds ratio (OR) for rs3786362 was 0.38, with a 95% confidence interval of 0.21 to 0.70."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True"}]}
{"chain_id": "chain_000031", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5721751", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5721751, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with decreased response to atenolol and hydrochlorothiazide in people with Hypertension as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The paper identifies that allele T of the SNP rs261316 in the gene ALDH1A2 is associated with an increased odds of uncontrolled blood pressure on a combination therapy of atenolol and hydrochlorothiazide. This indicates that the presence of allele T, not allele C, is associated with decreased response to the treatment in the context discussed."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs35123024 and atenolol, hydrochlorothiazide in Disease:Hypertension (PMCID PMC5721751), what OR was reported?", "answer": "3.71", "response": "For the variant rs35123024, the study reported an odds ratio (OR) of 3.71 (95% CI: 2.13\u20136.45, P=3.46E-06) in the PEAR study. In the INVEST white-Hispanic meta-analysis, it showed an OR of 1.72 (95% CI: 1.06\u20132.79, P=0.033)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000032", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC5558540", "num_turns": 2, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5558540, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC5558540, rs4141964 is associated with Toxicity outcomes for morphine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "The claim is not_reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC5558540 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMCID PMC5558540 reports a p-value for the association of rs4141964 with postoperative vomiting (p = 0.1767) and another one with clinical respiratory depression (p = 0.2519), which are considered toxicity outcomes for morphine."}]}
{"chain_id": "chain_000033", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC10193607", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC10193607, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with increased likelihood of transplant rejection when treated with tacrolimus in children with Kidney Transplantation as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1045642 and tacrolimus in Other:Kidney Transplantation (PMCID PMC10193607), what p-value was reported for this association?", "answer": "= 0.01", "response": "The reported p-value for the association of the rs1045642 (C3435T) polymorphism with the risk of acute rejection was 0.01 for the C allele, 0.008 for the CC genotype, and 0.001 for the CT genotype when compared to the non-acute rejection group."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "True."}]}
{"chain_id": "chain_000034", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC3164878", "num_turns": 2, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3164878, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC3164878, rs671531 is associated with Toxicity outcomes for fentanyl. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC3164878 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC3164878 does not report any quantitative statistic such as a p-value, odds ratio (OR), or confidence interval (CI) for the claim regarding rs671531 and toxicity outcomes for fentanyl."}]}
{"chain_id": "chain_000035", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3749570", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3749570, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with response to cyclophosphamide in people with Prostatic Neoplasms as compared to genotypes CG + GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2010963 and cyclophosphamide in Disease:Prostatic Neoplasms (PMCID PMC3749570), what p-value was reported for this association?", "answer": "= 0.0485", "response": "The p-value reported for the association between the rs2010963 genotype and the response to cyclophosphamide in prostate neoplasms was 0.0485."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000036", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC4660479", "num_turns": 2, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4660479, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC4660479, rs4149087 is associated with Toxicity outcomes for enalapril. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC4660479 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC4660479 does not report any quantitative statistic (p-value/OR/CI) for the claim related to rs4149087 and toxicity outcomes for enalapril."}]}
{"chain_id": "chain_000037", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC8426351", "num_turns": 2, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC8426351, is the following pharmacogenomic claim supported, contradicted, or not reported: Genotypes CT + TT is associated with decreased concentrations of rivaroxaban in men as compared to genotype CC. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC8426351 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "The claim regarding genotypes CT + TT and decreased concentrations of rivaroxaban in men compared to genotype CC is not reported in PMCID PMC8426351. Therefore, there is no quantitative statistic such as a p-value, odds ratio, or confidence interval provided for this claim in the paper."}]}
{"chain_id": "chain_000038", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5488790", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5488790, is the following pharmacogenomic claim supported or contradicted: UGT1A1 *6 + *28 is not associated with increased likelihood of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms or Lung Neoplasms as compared to UGT1A1 *1/*1. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The paper indicates that there was no significant association between UGT1A1 *6/*28 variants and severe neutropenia in lung and colorectal cancer patients as compared to wild-type UGT1A1 *1/*1."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of UGT1A1*1, UGT1A1*6, UGT1A1*28 and irinotecan in Other:Colorectal Neoplasms, Other:Lung Neoplasms (PMCID PMC5488790), what p-value was reported for this association?", "answer": "= 0.7", "response": "The p-value reported for the association of UGT1A1*6 and UGT1A1*28 with severe delayed diarrhea in colorectal cancer patients, when considered together, was p=0.028. However, for neutropenia, there was no significant association, and specific p-values are not provided for neutropenia in this context. For lung cancer, p-values were not significant for severe delayed diarrhea."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "True. A p-value of 0.028 is statistically significant at an alpha level of 0.05."}]}
{"chain_id": "chain_000039", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC3232196", "num_turns": 2, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3232196, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC3232196, rs1045642 is associated with Toxicity, Metabolism/PK outcomes for buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine, tramadol. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not_reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC3232196 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "PMCID PMC3232196 does not report any quantitative statistic for the claim regarding rs1045642 and its association with outcomes for buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine, or tramadol."}]}
{"chain_id": "chain_000040", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2072824", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2072824, is the following pharmacogenomic claim supported or contradicted: HLA-B *44:02 + *44:03 is associated with increased risk of Drug Hypersensitivity when exposed to trichloroethylene. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of HLA-B*44:02, HLA-B*44:03 and trichloroethylene in Toxicity (PMCID PMC2072824)?", "answer": 113, "response": "The study included 113 cases with TCE-induced hypersensitivity dermatitis for the examination of HLA-B*44 alleles."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000041", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC7156285", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC7156285, is the following pharmacogenomic claim supported or contradicted: HLA-A *31:01 is associated with increased risk of drug-induced liver injury when treated with carbamazepine. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of HLA-A*31:01 and carbamazepine in Toxicity (PMCID PMC7156285), what confidence interval was reported?", "answer": "2.47\u201323.67", "response": "The reported confidence interval for the association of HLA-A*31:01 with carbamazepine-induced toxicity, specifically CBZ-DILI (carbamazepine-induced drug-induced liver injury), is 95% CI 2.47\u201323.67."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000042", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC12098310", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC12098310, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT is associated with decreased likelihood of Progression-free survival and overall survival when treated with doxorubicin in people with Hepatocellular Carcinoma as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3787728 and doxorubicin in Other:Hepatocellular Carcinoma (PMCID PMC12098310), what p-value was reported for this association?", "answer": "= 0.045", "response": "The reported p-value for the association of rs3787728 with overall survival was 0.046 in the context of doxorubicin treatment in patients with hepatocellular carcinoma. For progression-free survival, the p-value was 0.054."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000043", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC11062152", "num_turns": 2, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11062152, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC11062152, UGT1A1*1, UGT1A1*6, UGT1A1*28 is associated with Dosage, Efficacy outcomes for fluorouracil, irinotecan, leucovorin. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC11062152 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMC11062152 reports p-values for associations between the UGT1A1*6 or *28 genotypes and decreased white blood cell and neutrophil counts, which relate to dosage and adverse outcomes during nal-IRI/FL treatment. The p-values reported are 0.009 for decreased white blood cell count and 0.017 for decreased neutrophil count associated with the homozygous (+/+) genotype."}]}
{"chain_id": "chain_000044", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC12308240", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC12308240, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased likelihood of Cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The paper identifies multiple genetic variants associated with anthracycline-induced cardiotoxicity in children, particularly focusing on those treated with doxorubicin or daunorubicin. The A allele of the *ABCC5* rs7627754 variant is associated with increased left ventricular ejection fraction and fractional shortening, suggesting a protective effect against cardiotoxicity when compared to other alleles. However, the general claim that alleles can influence cardiotoxicity is supported by the findings in the paper."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs17583889 and daunorubicin, doxorubicin in Other:Neoplasms (PMCID PMC12308240), what OR was reported?", "answer": "1.84", "response": "The study reported an odds ratio (OR) of 1.84 (95% CI 1.34\u20132.52) for the association of the variant rs17583889 with anthracycline-induced cardiotoxicity."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000045", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4519434", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4519434, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased risk of Heroin Dependence due to heroin as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The paper finds that the rs3778150-C allele, not the T allele, is associated with increased risk of heroin addiction."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "This annotation represents clinical_association evidence."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs511435 and heroin in Toxicity (PMCID PMC4519434), what OR was reported?", "answer": "1.2", "response": "The reported odds ratio (OR) for rs511435 in association with heroin addiction was 1.20."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "False. The confidence interval for the OR of rs511435 in association with heroin addiction was not provided in the exact phrasing you requested. However, from the given table, for rs511435 tested in African Americans in the Urban Health Study, the confidence interval is 1.10 (0.97-1.23), which includes the null value of 1.0. \n\nPlease note, the OR and confidence interval specifics might vary contextually in different parts, so it's important to refer back to the correct table for precise readings. If by \"toxicity\" you refer specifically to a detailed subset within the paper that diverges from the typical contexts, that exact segment should be located for pointed cross-reference."}]}
{"chain_id": "chain_000046", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC6773496", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC6773496, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs1801253 and atenolol, metoprolol in Other:Tachycardia (PMCID PMC6773496)?", "answer": 459, "response": "The study does not provide the exact number of cases specifically for rs1801253 in individuals with Tachycardia in relation to atenolol or metoprolol treatment. The focus is on heart rate response generally in hypertensive patients across the clinical trials (PEAR, PEAR-2, and INVEST), without specifying Tachycardia as a separate condition."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000047", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2042718", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2042718, is the following pharmacogenomic claim supported or contradicted: CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*17. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2D6*1, CYP2D6*2, CYP2D6*17 and debrisoquine in Metabolism/PK (PMCID PMC2042718), what p-value was reported for this association?", "answer": "< 0.001", "response": "The study does not explicitly report a p-value for the association between CYP2D6*17 and debrisoquine metabolism in the available abstract and metadata provided. To find this specific piece of information, you would need to refer to the full text of the article."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": true, "response": "Based on the information provided in the abstract and metadata, it is not possible to determine whether the association would remain significant at an alpha level of 0.01 since the specific p-value is not given. Therefore, I cannot conclusively answer true or false without additional data from the full text."}]}
{"chain_id": "chain_000048", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5354739", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5354739, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased concentrations of methotrexate in children with as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper does not provide information on a specific SNP where allele C is compared to allele T regarding increased concentrations of methotrexate in children with osteosarcoma. Information on specific associations typically includes details on which particular SNP and alleles are relevant. Without this key detail, it is not possible to make a determination based on the information you have provided. Therefore, the claim is neither supported nor contradicted by the information from PMCID PMC5354739."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs9282564 and methotrexate in Metabolism/PK (PMCID PMC5354739)?", "answer": 59, "response": "The study does not specify the exact number of cases included solely for the analysis of the rs9282564 SNP in relation to methotrexate metabolism/pharmacokinetics. However, the overall analysis included 59 patients with osteosarcoma."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True"}]}
{"chain_id": "chain_000049", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC11758033", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11758033, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "contradicted"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs121918623 and antiepileptics in Other:Epilepsy (PMCID PMC11758033), what p-value was reported for this association?", "answer": "= 1", "response": "The p-value reported for the association of rs121918623 with antiepileptics in epilepsy was 1.00."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
